Salarius Pharmaceuticals, Inc. has amended its merger agreement with Decoy Therapeutics on March 28, 2025, fixing ownership percentages at 14.1% for Salarius and 85.9% for Decoy after the merger, and received a notice from Nasdaq on March 26, 2025, regarding non-compliance with listing requirements due to insufficient stockholders' equity.